Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -13851.65% is 1825% below its 5-year average of -719.67%, near the low end of its 5-year range (-13851.65%–1957.82%).
178.42% below its 12-month average of -4975.06%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2013 (2012-10-31): -5547.89%.
EBITDA MARGIN
-13851.65%
EBITDA MARGIN AVG TTM
-4975.06%
EBITDA MARGIN AVG 3Y
-1827.52%
EBITDA MARGIN AVG 5Y
-719.67%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-178.42%
CURRENT VS 3Y AVG
-657.95%
CURRENT VS 5Y AVG
-1824.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
PharmaCyte Biotech, Inc.
Market Cap
$4.53M
EBITDA Margin
-13851.65%
TTM Avg
-4975.06%
3Y Avg
-1827.52%
5Y Avg
-719.67%
Market Cap
$4.40M
EBITDA Margin
-445.85%
TTM Avg
-1797.00%
3Y Avg
-2252.67%
5Y Avg
-1514.30%
Market Cap
$4.71M
EBITDA Margin
-4837.99%
TTM Avg
-4449.42%
3Y Avg
-4104.15%
5Y Avg
-4023.55%
Market Cap
$4.72M
EBITDA Margin
-1127.44%
TTM Avg
-14514.89%
3Y Avg
-11694.21%
5Y Avg
-11694.21%
Market Cap
$4.32M
EBITDA Margin
-159.06%
TTM Avg
-237.19%
3Y Avg
-222.87%
5Y Avg
-159.05%
Market Cap
$4.86M
EBITDA Margin
-95.23%
TTM Avg
-128.63%
3Y Avg
-206.76%
5Y Avg
-750.38%
Market Cap
$4.21M
EBITDA Margin
-38402.78%
TTM Avg
-17909.83%
3Y Avg
-9620.57%
5Y Avg
-7243.11%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | $4.53M | -13851.65% | -4975.06% | -1827.52% | -719.67% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.40M | -445.85% | -1797.00% | -2252.67% | -1514.30% |
| CalciMedica, Inc. (CALC)vs › | $4.69M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $4.71M | -4837.99% | -4449.42% | -4104.15% | -4023.55% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.72M | -1127.44% | -14514.89% | -11694.21% | -11694.21% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | -159.06% | -237.19% | -222.87% | -159.05% |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.86M | -95.23% | -128.63% | -206.76% | -750.38% |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.21M | -38402.78% | -17909.83% | -9620.57% | -7243.11% |
| GRI Bio, Inc. (GRI)vs › | $4.15M | -1456.00% | -1456.00% | -1456.00% | -1456.00% |
Gross Margin
0.0%
EBITDA Margin
-13851.6%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2012-10-31 | -5547.89% |
| 2012-07-31 | -8131.39% |
| 2012-04-30 | -7215.45% |
| 2012-01-31 | -1985.64% |
| 2011-10-31 | -1994.93% |
| 2011-07-31 | -3259.17% |
| 2011-04-30 | -415.68% |
| 2011-01-31 | -185.94% |
| 2010-10-31 | -51.76% |
| 2010-07-31 | -249.67% |
| 2010-04-30 | 1957.82% |
| 2010-01-31 | -2338.27% |
| 2009-10-31 | -643.69% |
| 2009-07-31 | -992.88% |
| 2009-04-30 | -5697.17% |
| 2009-01-31 | -677.76% |
| 2008-10-31 | -214.55% |
| 2008-07-31 | -161.03% |
| 2008-04-30 | -471.30% |
| 2008-01-31 | -293.06% |
| 2007-10-31 | -256.83% |
| 2007-07-31 | -281.21% |
| 2007-04-30 | -287.00% |
| 2007-01-31 | -928.19% |
| 2006-10-31 | -318.30% |
| 2006-07-31 | -220.43% |
| 2006-04-30 | -1270.95% |
| 2006-01-31 | -610.01% |
| 2005-07-31 | -1831.24% |
| 2005-04-30 | -5352.31% |
| 2005-01-31 | -193.96% |
| 2004-10-31 | -3128.60% |
| 2004-07-31 | -1903.05% |
